## Summer Training Institute for Randomized Clinical Trials Involving Behavioral Interventions, 2002

# Tab 2 Daily Schedules and Study Groups

#### **Table of Contents**

Overview	1
Financial Disclosure Statements	1
Lecture Evaluations	1
Study Groups	2
Which Study Group am I in?	
Overview of Course Schedule	3
Model Daily Schedule	4
Time	4
Activity	4
Daily Topics	
Week 1	
Week 2	6

#### Overview

**Tabs A – K** provide the schedules for the lectures and Study Groups. Besides listing the theme for the day and the lectures, we are providing reprints of required readings for each lecture. In some instances, we are also suggesting additional readings for future reference. (See Tab 6 for a complete bibliography. Reprints of *Required Readings* are provided at Tab 2, immediately following the associated lecture schedule. Reprints of some *suggested reading* are provided at Tab 6 in alphabetical order by author.)

#### **Financial Disclosure Statements**

In accordance with the policies of the Accreditation Council for Continuing Medical Education and of the American Psychological Association, we are providing disclosure statements of speakers' financial interests in or relationships with the manufacturer(s) of any commercial product(s) that may be discussed during the course. Please review these in advance of each lecture. They may be found at **Tab 3, B**.

#### **Lecture Evaluations**

Please complete and hand in the **Lecture Evaluation Forms** for the daily presentations either immediately following the lecture or at the end of the day. You will find the forms in this Resource Binder for each day's schedule at Tab 2, A-K.

At the end of the course, please complete the **Overall Course Evaluation Form**, which you can find at Tab 1. (See the Table of Contents for Tab 1).

#### Daily Schedules and Study Groups

#### **Study Groups**

Except as noted, we will divide into five Study Groups to discuss the daily themes, lectures, and readings as well as to eventually design RCTs! Please note to which Study Group you have been assigned. During the first week of the course, the Study Groups will discuss issues and work on assignments associated with the daily lectures. During the second week, each Study Group will be assigned a topic on which to design a RCT. The Study Groups will present their designs for discussion and friendly critique on August 8<sup>th</sup> and 9<sup>th</sup>.

#### Which Study Group am I in?

Group 1

Steven Ames Stacy Kaltman Maria Aranda Golda Ginsburg Catherine Davis

Kristin Corazzini Gomez Location: Jefferson Room

Faculty:

Week 1: Lynda Powell

Baruch Brody

Week 2 Nancy Frasure-Smith

Ronald Abeles

Group 2

Melina Aldorfer Steven Rothschild Bonnie Gance-Cleveland Monica Johnson-Mitchell

Jackie Gollan Nadine Revheim

Location: West Room

Faculty:

Week 1: Michael Proschan

Frank Keefe

Week 2: Robert Kaplan

**Group 3** 

Rhonda Boyd Melicia Whitt Matthew Allison Sherry Pagoto Bettina Beech Michael Kennedy

Anita Fernander

Location: South Room

Faculty:

Week 1: Sheryl Kelsey

Ronald Abeles

Week 2: Nancy Houston-Miller

Peter Kaufmann

**Group 4** 

Kristin Vickers Denise Chavira Olga Bazhenova Moira Rynn Julie Locher Mary Cooley James Carmody

Location: Board Room

Faculty:

Week 1: Janet Wittes

Peter Kaufmann

Week 2: Sherry Willis

Michael Proschan

Group 5

Jill Bennet

Michael de Arellano Denise Bonds Risa Weisberg Isabel Scarinci Kimberly Lochner

Location: Studio Room

Faculty:

Week 1: Karina Davidson
Week 2: Nina Schooler

Janet Wittes

Tab 2, Page 2 12/31/2002

## Summer Training Institute for Randomized Clinical Trials Involving Behavioral Interventions, 2002

	Overview of Course Schedule			
Tab	Tab Date Theme			
A	July 28 Sunday Evening	Welcome and Orientation		
В	July 29 Monday	History and Methods of RCTs		
С	July 30 Tuesday	Research Designs		
D	July 31 Wednesday	Designing RCTs		
Е	August 1 Thursday	Research Ethics		
F	August 2 Friday	Defining and Selecting Participants		
	August 3 – 4 (Saturday and Sunday): Recreation			
G	August 4 Sunday Evening	Getting a Research Grant from the NIH		
Н	August 5 Monday	Psychological Assessment, Fidelity, and Adherence		
I	August 6 Tuesday	Quality Control		
J	August 7 Wednesday	Multi-center RCTs		
K	August 8 Thursday	Presentations by Study Groups Graduation Party		
	August 9 Friday	Presentations by Study Groups Farewell		

#### Daily Schedules and Study Groups

## **Model Daily Schedule**

Unless otherwise noted, we will schedule the lectures, breaks, and discussion groups following this time plan. **Warning**: Subject to frequent, last minute changes!

Time	Activity
7:00 – 8:00 AM	Breakfast
8:00 – 9:00 AM	Lecture 1
9:00 – 9:20 AM	Discussion: Questions and Answers
9:20 – 9:30 AM	Refreshment Break
9:30 – 10:30 AM	Lecture 2
10:30 – 10:50 AM	Discussion: Questions and Answers
10:50 – 11:00 AM	Break
11:00 AM - 12:00 PM	Lecture 3
12:00 – 12:20 PM	Discussion: Questions and Answers
12:20 – 1:30 PM	Lunch
1:30 – 3:30 PM	Study Groups
3:30 – 6:00 PM	Free Time
6:00 – 7:00 PM	Dinner
7:00 – 8:00 PM	Occasional / Optional Lecture or Discussion

Tab 2, Page 4 12/31/2002

## Summer Institute for Randomized Clinical Trials Involving Behavioral Interventions, 2002

## **Daily Topics**

#### Week 1

Tab A July 28, Sunday	Welcome and Introductions	Ronald Abeles Peter Kaufmann
Tab B July 29, Monday	History & Philosophy of RCTs	Lynda Powell
	Hypothesis Specification	Michael Proschan
	Basic Study Design	Sheryl Kelsey
Tab C July 30, Tuesday	Study Populations; Randomization, and Unit of Randomization	Sheryl Kelsey
	Sample Size	Janet Wittes
	External & Internal Validity (Effectiveness vs. Efficacy)	Karina Davidson
	A Case Study (Evening Discussion)	
Tab D July 31, Wednesday	Control Groups, Blindness/Masking, Behavioral "Placebo"	Frank Keefe
	Selecting Treatment and Maintaining Fidelity	Karina Davidson
	Emerging Topics	Faculty & Fellows
Tab E August 1, Thursday	Criteria for Ethically Acceptable Clinical Trials	Baruch Brody
	Ethnic Consideration for Inclusion of Special Population in RCTs	Baruch Brody
	DSMBs	Sheryl Kelsey
	Evening: Managing Your Career	Faculty panel
Tab F	Recruitment and Retention	Lynda Powell
August 2, Friday	Analytic Dilemmas	Janet Wittes
	Statistical Modeling	Michael Proschan
Tab G August 3, Saturday	Recreation	All

## Daily Schedules and Study Groups

## Week 2

Tab G	Recreation	All
August 4, Sunday	Evening Lecture: Applying for NIH Grants	Ronald Abeles
Tab H August 5, Monday	Defining and Selecting Participants (inclusion and exclusion criteria)	Nina Schooler & Sherry Willis
	Linking Hypotheses, Outcomes, and Assessments	Nina Schooler
	Quality of Life	Robert Kaplan
Tab I August 6, Tuesday	Treatment Adherence by Participants	Nancy Houston-Miller & Sherry Willis
	Cost-effectiveness	Robert Kaplan
	Emerging Topics	Faculty & Fellows
	Optional Evening Lecture: Meta-analysis	Michael Proschan
Tab J	Missing Data	Janet Wittes
August 7, Wednesday	Survival Analysis	Michael Proschan
	Subgroup Analysis	Nancy Frasure-Smith
Tab K	Study Group Reports	Fellows
August 8, Thursday	Graduation Celebration	
Tab K	Study Group Reports	Fellows
August 9, Friday	Adjournment	

Tab 2, Page 6 12/31/2002

## Tab A July 28, 2002 Welcome and Introductions

1:00 PM	Arrival and registration	Lobby
6:00 – 7:30 PM	Dinner	Main dinning room
7:30 – 9:00 PM	Welcome and Orientation	Jefferson Room
	Introduction, Goals, and Issues	Ronald Abeles and Peter Kaufmann
	Issues in Behavioral RCTs	Peter Kaufmann

Tab 2, Page 7

#### Tab A Sunday, August 10, 2001

#### Welcome and Introductions

Please rate tonight's presentation, and all subsequent lectures, using the following scale and give us your comments. Only cumulative (i.e., non-identifiable) information will be provided to the faculty. Your input will be used to improve future offerings of this Summer Training Institute.

## **Rating of Individual Presentations**

## Peter Kaufmann, Issues in Behavioral RCTs

2 = Below Average	4 = Above Average 5 = Excellent NA= Not applicable
Criteria	Comments (Use back of page as necessary)
Content 1 2 3 4 5 NA	
Audio-visuals 1 2 3 4 5 NA	
Knowledge and expertise 1 2 3 4 5 NA	
Teaching ability 1 2 3 4 5 NA	

## History and Issues in RCTs

29 July, Monday	Lecture 1: History & Philosophy of RCTs	Lynda Powell
	Required	
	• Textbook, Ch. 1	
	Lecture 2: Hypothesis specification: primary/secondary outcomes.	Michael Proschan
	Required	
	• Textbook, Ch. 2	
	Suggested	
	<ul> <li>Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators.         N Engl J Med. 1989 Aug 10; 321(6): 406-12     </li> </ul>	
	Lecture 3: Basic Study Design	Sheryl Kelsey
	Required	
	• Textbook, Chapters 2 and. 4	

## History and Issues in RCTs

## **Rating of Individual Presentations**

## Lynda Powell History and Philosophy of RCTs

Scale: 1 = Poor 2 = Below Average 3 = Average	4 = Above Average 5 = Excellent NA= Not applicable
Criteria	Comments (Use back of page as necessary)
Content 1 2 3 4 5 NA	
Audio-visuals 1 2 3 4 5 NA	
Knowledge and expertise 1 2 3 4 5 NA	
Teaching ability 1 2 3 4 5 NA	

## History and Issues in RCTs

## **Rating of Individual Presentations**

## Michael Proschan Hypothesis Specification: Primary/Secondary outcomes

2 = Below Average	4 = Above Average 5 = Excellent NA= Not applicable
Criteria	Comments (Use back of page as necessary)
Content 1 2 3 4 5 NA	
Audio-visuals 1 2 3 4 5 NA	
Knowledge and expertise 1 2 3 4 5 NA	
Teaching ability 1 2 3 4 5 NA	

## History and Issues in RCTs

## **Rating of Individual Presentations**

## Sheryl Kelsey Basic Study Design

2 = Below Average	4 = Above Average 5 = Excellent NA= Not applicable
Criteria	Comments (Use back of page as necessary)
Content 1 2 3 4 5 NA	
Audio-visuals 1 2 3 4 5 NA	
Knowledge and expertise 1 2 3 4 5 NA	
Teaching ability 1 2 3 4 5 NA	

## Samples and Populations

30 Jul, Tuesday	Lecture 1: Study population; randomization; unit of randomization	Sheryl Kelsey
	Required	
	• Textbook, Chapters 3 & 5.	
	Sample size	Janet Wittes
	Required	
	<ul> <li>Textbook, Ch 7</li> <li>J. Wittes, Sample Size Calculations for Ramdomized Controlled Trials, Epidemiologic Reviews, 2002: 24(1), 39-53</li> </ul>	
	Lecture 3: External and internal validity	Karina Davidson
	Required	
	<ul> <li>Slack, M. K. &amp; Draugalis, J. R., Establishing the internal and external validity of experimental studies. <i>American Journal of Health-Systems Pharm.</i>, 2001, 58, 2173-2184.</li> <li>Glasgow, R. E., Vogt, T. M., &amp; Boles, S. M. Evaluating the public health impact of health promotion interventions: The RE-AIM framework. <i>American Journal of Public Health</i>, 1999, 89, 1322-1327.</li> <li>Suggested</li> </ul>	
	<ul> <li>Miklowitz, D. J., Clarkin, J.F. Balancing internal and external validity. <i>Prevention &amp; Treatment</i>, 1999, 2, (http://www.journals.apa.org/prevention/volume2/toc-mar21-99.html)</li> <li>Persons, J. B. &amp; Silberschatz, G. Are results of randomized controlled trials useful to psychotherapists? <i>Journal of Consulting and Clinical Psychology</i>, 1998, 66, 126-135.</li> </ul>	

Tab L: August 10, 2001

<b>Evening Session: A Case Study</b>	All
Required	
<ul> <li>L. Rosa, et al., A close look at therapeutic touch, JAMA, April 1, 1998, 279(13): 1005-1010</li> <li>An Even Closer Look at Therapeutic Touch: Letters to the Editor, JAMA, December 9, 1998, 279(22): 1905-1908.</li> </ul>	

Tab 2, Page 20 12/31/2002

## Samples and Populations

## **Rating of Individual Presentations**

## Sheryl Kelsey Study Populations and Randomization

2 = Below Average	4 = Above Average 5 = Excellent NA= Not applicable
Criteria	Comments (Use back of page as necessary)
Content 1 2 3 4 5 NA	
Audio-visuals 1 2 3 4 5 NA	
Knowledge and expertise 1 2 3 4 5 NA	
Teaching ability 1 2 3 4 5 NA	

## Samples and Populations

## **Rating of Individual Presentations**

## Janet Wittes Sample Size

Scale: 1 = Poor 2 = Below Average 3 = Average	4 = Above Average 5 = Excellent NA= Not applicable
Criteria	Comments (Use back of page as necessary)
Content 1 2 3 4 5 NA	
Audio-visuals 1 2 3 4 5 NA	
Knowledge and expertise 1 2 3 4 5 NA	
Teaching ability 1 2 3 4 5 NA	

## Samples and Populations

## **Rating of Individual Presentations**

## Karina Davidson External and Internal Validity

Scale: 1 = Poor 2 = Below Average 3 = Average	4 = Above Average 5 = Excellent NA= Not applicable
Criteria	Comments (Use back of page as necessary)
Content 1 2 3 4 5 NA	
Audio-visuals 1 2 3 4 5 NA	
Knowledge and expertise	
Teaching ability 1 2 3 4 5 NA	

## Samples and Populations

## **Rating of Individual Presentations**

## Group Discussion A Case Study: A Closer Look at Therapeutic Touch

2 = Below Average	4 = Above Average 5 = Excellent NA= Not applicable
Criteria	Comments (Use back of page as necessary)
Content 1 2 3 4 5 NA	
Usefulness in illustrating RCT design issues 1 2 3 4 5 NA	
Quality of discussion 1 2 3 4 5 NA	
Success as a teaching devise 1 2 3 4 5 NA	

## Treatment and Control Groups

31 Jul, Wednesday	Lecture 1: Control groups, blindness/masking, behavioral "placebo."	Frank Keefe
	<ul> <li>Textbook, Ch. 6</li> <li>Hrobjartsson A and Gotzsche PC, Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment, <i>NEJM</i>, 2001, <i>344</i>: 1594-602</li> <li>Turner JA, et al., The importance of placebo effects in pain treatment and research, <i>JAMA</i>, 1994, <i>271</i>: 1609-14</li> <li>Suggested</li> <li>Beecher, HK, The powerful placebo, <i>JAMA</i>, 1955, <i>27</i>: 1602-6</li> </ul>	
	Lecture 2: Selecting treatments and maintaining fidelity	Karina Davidson
	Required	
	<ul> <li>Textbook, Ch. 10</li> <li>Lichstein, K. L., Riedel, B. W., &amp; Grieve, R. (1994). Fair test of clinical trials: A treatment implementation model. <i>Advanced Behavioral Research Therapy</i>, 1994, 16, 1-29.</li> </ul>	
	Suggested	
	Moncher, F. J. & Prinz, R. J. Treatment fidelity in outcome studies. <i>Clinical</i> <i>Psychology Review</i> , 1991, <i>11</i> , 247-266.	
	Lecture 3: Emerging Topics	Faculty and Fellows

## **Treatment and Control Groups**

## **Rating of Individual Presentations**

## Frank Keefe Control Groups

Scale: 1 = Poor 2 = Below Average 3 = Average	4 = Above Average 5 = Excellent NA= Not applicable
Criteria	Comments (Use back of page as necessary)
Content 1 2 3 4 5 NA	
Audio-visuals 1 2 3 4 5 NA	
Knowledge and expertise	
1 2 3 4 5 NA	
Teaching ability 1 2 3 4 5 NA	

Tab 2, Page 31

## Treatment and Control Groups

## **Rating of Individual Presentations**

## Karina Davidson Selecting Treatments

2 = Below Average	4 = Above Average 5 = Excellent NA= Not applicable
Criteria	Comments (Use back of page as necessary)
Content 1 2 3 4 5 NA	
Audio-visuals 1 2 3 4 5 NA	
Knowledge and expertise 1 2 3 4 5 NA	
Teaching ability 1 2 3 4 5 NA	

## Treatment and Control Groups

## **Rating of Individual Presentations**

Fill in name(s)

## **Emerging Topics**

2 = Below Average	4 = Above Average 5 = Excellent NA= Not applicable
Criteria	Comments (Use back of page as necessary)
Content 1 2 3 4 5 NA	
Audio-visuals 1 2 3 4 5 NA	
Knowledge and expertise 1 2 3 4 5 NA	
Teaching ability 1 2 3 4 5 NA	

#### Ethical Issues in RCTs

1 Aug, Thursday	Criteria for Ethically Acceptable Clinical Trials  Required	Baruch Brody
	<ul> <li>The Belmont Report: Ethical principles and guidelines for the protection of human subjects of research, April 18, 1979 (Department of Health, Education, and Welfare)</li> <li>Code of Federal Regulations, Title 45, Part 46, Subpart A, Projection of Human Subjects.</li> </ul>	
	Inclusion and Exclusion in Clinical Trials: Special Populations	Baruch Brody
	Required	
	<ul> <li>National Institutes of Health Policy and Guidelines for the Inclusion of Children as Participants in Research Involving Human Subjects, March 6, 1998.</li> <li>National Institutes of Health Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical Research, March 18, 1994</li> </ul>	
	Lecture 3: DSMBs: Composition, functions	Sheryl Kelsey
	Required	
	<ul> <li>Textbook, Chapters. 11 and 15</li> <li>Wittes J., Data safety monitoring boards: A brief introduction.  Biopharmaceutical Report, 2000, 8(1): 1-11.</li> </ul>	
	<b>Evening Panel: Career Management</b>	All Faculty

#### Ethical Issues in RCTs

### **Rating of Individual Presentations**

## Baruch Brody Criteria for Ethically Acceptable Clinical Trials

2 = Below Average	4 = Above Average 5 = Excellent NA= Not applicable
Criteria	Comments (Use back of page as necessary)
Content 1 2 3 4 5 NA	
Audio-visuals 1 2 3 4 5 NA	
Knowledge and expertise 1 2 3 4 5 NA	
Teaching ability 1 2 3 4 5 NA	

#### Ethical Issues in RCTs

### **Rating of Individual Presentations**

## Baruch Brody Ethnic Consideration for Inclusion of Special Population in RCTs

2 = Below Average	4 = Above Average 5 = Excellent NA= Not applicable
Criteria	Comments (Use back of page as necessary)
Content 1 2 3 4 5 NA	
Audio-visuals 1 2 3 4 5 NA	
Knowledge and expertise 1 2 3 4 5 NA	
Teaching ability 1 2 3 4 5 NA	

#### Ethical Issues in RCTs

## **Rating of Individual Presentations**

## Sheryl Kelsey Data Safety Monitoring Boards (DSMB)

2 = Below Average	4 = Above Average 5 = Excellent NA= Not applicable
Criteria	Comments (Use back of page as necessary)
Content 1 2 3 4 5 NA	
Audio-visuals 1 2 3 4 5 NA	
Knowledge and expertise 1 2 3 4 5 NA	
Teaching ability 1 2 3 4 5 NA	

#### Recruitment and Analysis

2 Aug, Friday	Recruitment and Retention of Participants	Lynda Powell
	Required	
	• Textbook, Ch. 9 & 13	
	Analytic Dilemmas	Janet Wittes
	Required	
	<ul> <li>Textbook, Ch. 5 &amp; 16</li> <li>Yusuf, S., et al., Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials, JAMA, 1991, 266 (1), 93-99.</li> <li>Suggested</li> </ul>	
	<ul> <li>Lavori, P. W., Dawson R. Designing for intent-to-treat. <i>Drug Info J.</i>, 2001, 35:1079-1086</li> <li>Lavori P.W., Clinical trials in psychiatry: should protocol deviation censor patient data?         Neuropsychopharmaology, 1992, 6:39-47     </li> </ul>	
	Statistical Modeling; covariate adjustment	Michael Proschan
	Required	
	• Textbook, pp. 297-304	

#### Recruitment and Analysis

## **Rating of Individual Presentations**

# Lynda Powell Recruitment and Retention

2 = Below Average	4 = Above Average 5 = Excellent
3 = Average	NA= Not applicable
Criteria	Comments (Use back of page as necessary)
Content 1 2 3 4 5 NA	
Audio-visuals 1 2 3 4 5 NA	
Knowledge and expertise	
1 2 3 4 5 NA	
Teaching ability  1 2 3 4 5 NA	

#### Recruitment and Analysis

### **Rating of Individual Presentations**

#### Janet Wittes Analytic Dilemmas

2 = Below Average	4 = Above Average 5 = Excellent NA= Not applicable
Criteria	Comments (Use back of page as necessary)
Content 1 2 3 4 5 NA	
Audio-visuals 1 2 3 4 5 NA	
Knowledge and expertise 1 2 3 4 5 NA	
Teaching ability 1 2 3 4 5 NA	

Tab 2, Page 49

#### Recruitment and Analysis

## **Rating of Individual Presentations**

#### Michael Proschan Statistical Modeling

Scale: 1 = Poor 2 = Below Average 3 = Average	4 = Above Average 5 = Excellent NA= Not applicable
Criteria	Comments (Use back of page as necessary)
Content 1 2 3 4 5 NA	
Audio-visuals 1 2 3 4 5 NA	
Knowledge and expertise 1 2 3 4 5 NA	
Teaching ability 1 2 3 4 5 NA	

#### Tab G Saturday and Sunday, August 3 - 4, 2002

#### Recreation and Grant Writing Strategies

3 – 4 Aug, Sat & Sun	Recreation	See Tab 5.
4 Aug, Sunday Evening	Applying for an NIH Grant	Ronald Abeles

#### Tab G Saturday and Sunday, August 3 - 4, 2002

Recreation and Grant Writing Strategies

#### **Rating of Individual Presentations**

## Ronald Abeles Applying for NIH Grants

2 = Below Average	4 = Above Average 5 = Excellent NA= Not applicable
Criteria	Comments (Use back of page as necessary)
Content 1 2 3 4 5 NA	
Audio-visuals 1 2 3 4 5 NA	
Knowledge and expertise 1 2 3 4 5 NA	
Teaching ability 1 2 3 4 5 NA	

## Participants, Hypotheses, and Outcomes

5 Aug, Monday	Lecture 1: Defining & selecting participants; eligibility (inclusion/exclusion criteria)  Required  Textbook, Ch. 9 Meinert C. L. Clinical Trials: Design, Conduct and Analysis. New York, NY: Oxford University Press, 1986, Chapter 14, pp. 149-158.  Suggested Textbook, Ch. 4	Nina Schooler and Sherry Willis
	Lecture 2: Linking hypotheses, outcomes, and assessment measures; hypothesis specification  Required  • To be announced.  Suggested	Nina Schooler
	• To be announced.	
	<ul> <li>Lecture 3: Health-related Quality of Life Required</li> <li>R. M. Kaplan, Quality of Life and Chronic Illness, in A.Christensen and M. Antoni (eds.), Chronic Physical Disorders: Behavioral Medicine's Perspective. Blackwell Publishing, 2002</li> <li>Scientific Advisory Committee of the Medical Outcome Trust, Assessing health status and quality-of-life instruments, Quality of Life Research, 2002, 11: 193-205.</li> <li>Suggested</li> <li>Textbook, Ch. 12</li> </ul>	Robert Kaplan

Tab 2, Page 57

Tab H: Monday, August 5, 2002

Tab 2, Page 58 12/31/2002

Participants, Hypotheses, and Outcomes

#### **Rating of Individual Presentations**

# Nina Schooler and Sherry Willis Defining and Selecting Participants

2 = Below Average	4 = Above Average 5 = Excellent NA= Not applicable
Criteria	Comments (Use back of page as necessary)
Content 1 2 3 4 5 NA	
Audio-visuals 1 2 3 4 5 NA	
Knowledge and expertise 1 2 3 4 5 NA	
Teaching ability 1 2 3 4 5 NA	

Participants, Hypotheses, and Outcomes

#### **Rating of Individual Presentations**

#### Nina Schooler Linking Hypotheses and Outcomes

Scale: 1 = Poor 2 = Below Average 3 = Average	4 = Above Average 5 = Excellent NA= Not applicable
Criteria	Comments (Use back of page as necessary)
Content 1 2 3 4 5 NA	
Audio-visuals 1 2 3 4 5 NA	
Knowledge and expertise	
Teaching ability 1 2 3 4 5 NA	

#### Participants, Hypotheses, and Outcomes

#### **Rating of Individual Presentations**

## Robert Kaplan Health-related Quality of Life

2 = Below Average	4 = Above Average 5 = Excellent NA= Not applicable
Criteria	Comments (Use back of page as necessary)
Content 1 2 3 4 5 NA	
Audio-visuals 1 2 3 4 5 NA	
Knowledge and expertise 1 2 3 4 5 NA	
Teaching ability 1 2 3 4 5 NA	

#### Adherence and Cost-effectiveness

6 Aug, Tuesday	Lecture 1: Treatment Adherence by Participants  Required  • Textbook, Ch. 9 & 13  Suggested	Nancy Houston- Miller and Sherry Willis
	• To be announced.  Lecture 2: Cost-effectiveness	Robert Kaplan
	Required	- 1100 <b>411 12</b> 0 p.m.:
	• Kaplan RM and Groessl EJ, Applications of cost-effectiveness analysis in behavioral medicine, <i>JCCP</i> , 2002, 70(3): 482-493	
	Suggested	
	• Goldman, et al., The effect of risk factor reductions between 1981 and 1990 on CHD incidence, prevalence, and mortality and cost, Journal of the American College of Cardiology, 2001, 38(4): 1012-1017.	
	<b>Lecture 3:</b> Emerging Topics	Faculty and Fellows
	Optional Evening Lecture Meta-analysis and integrating across RCTs	Michael Proschan
	Required	
	• Textbook, pp. 308-317 Suggested	
	<ul> <li>Geller NL, Proschan M, Meta-analysis of clinical trials: a consumer's guide. <i>J Biopharm Stat.</i> 1996 Nov; 6(4): 377-94</li> <li>Thomson SG, Controversies in meta-analysis: the case of the trials of serum cholesterol reduction. <i>Stat Methods Med Res.</i> 1993; 2(2): 173-92</li> </ul>	

#### Adherence and Cost-effectiveness

### **Rating of Individual Presentations**

#### Nancy Houston-Miller and Sherry Wills Treatment Adherence by Participants

2 = Below Average	4 = Above Average 5 = Excellent NA= Not applicable
Criteria	Comments (Use back of page as necessary)
Content 1 2 3 4 5 NA	
Audio-visuals 1 2 3 4 5 NA	
Knowledge and expertise 1 2 3 4 5 NA	
Teaching ability 1 2 3 4 5 NA	

#### Adherence and Cost-effectiveness

### **Rating of Individual Presentations**

#### Robert Kaplan Cost-effectiveness

Scale: 1 = Poor 2 = Below Average 3 = Average	4 = Above Average 5 = Excellent NA= Not applicable
Criteria	Comments (Use back of page as necessary)
Content 1 2 3 4 5 NA	
Audio-visuals 1 2 3 4 5 NA	
Knowledge and expertise	
1 2 3 4 5 NA	
Teaching ability 1 2 3 4 5 NA	

#### Adherence and Cost-effectiveness

### **Rating of Individual Presentations**

# (Insert Name of Speaker) Emerging Topics

2 = Below Average	4 = Above Average 5 = Excellent NA= Not applicable
Criteria	Comments (Use back of page as necessary)
Content 1 2 3 4 5 NA	
Audio-visuals 1 2 3 4 5 NA	
Knowledge and expertise 1 2 3 4 5 NA	
Teaching ability 1 2 3 4 5 NA	

#### Adherence and Cost-effectiveness

### **Rating of Individual Presentations**

#### Meta-analysis Michael Proschan

Scale: 1 = Poor 2 = Below Average 3 = Average	4 = Above Average 5 = Excellent NA= Not applicable
Criteria	Comments (Use back of page as necessary)
Content 1 2 3 4 5 NA	
Audio-visuals 1 2 3 4 5 NA	
Knowledge and expertise	
Teaching ability 1 2 3 4 5 NA	

#### Issues in Data Analysis

7 Aug, Wednesday	Missing Data	Janet Wittes
	Required:	
	• Textbook, Ch. 16	
	Survival Analysis	Michael Proschan,
	Required:	
	• Textbook, Ch. 14	
	Suggested	
	<ul> <li>Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. <i>JAMA</i>. 1998 Aug 19; 280 (7): 605-13</li> </ul>	

Tab H: Monday, August 5, 2002

#### **Subgroup Analysis**

#### Required

- Textbook, Ch. 16, pp. 304-306
- Yusef S, Wittes J, Probstfield J, Tyroler HA, Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials, *JAMA*, 1991; 266(1): 93-98.

#### Suggested

- Buyse ME, Analysis of clinical trial outcomes: Some comments on subgroup analyses. *Control Clin Trials*, 1989; *10*: 187s-194s
- Furberg CD, et al., Subgroup interaction in the Heart and Estrogen/Progestin Replacement Study: Lessons Learned. *Circulation*, 2002; *105*: 917-922.
- Oxman AD, Guyatt GH. A consumer's guide t subgroup analysis, *Ann Intern Med*, 1992 A.D.; *116*(1): 78-84

Nancy Frasure-Smth

Tab 2, Page 76 12/31/2002

#### Issues in Data Analysis

## **Rating of Individual Presentations**

#### Janet Wittes Missing Data

2 = Below Average	4 = Above Average 5 = Excellent NA= Not applicable
Criteria	Comments (Use back of page as necessary)
Content 1 2 3 4 5 NA	
Audio-visuals 1 2 3 4 5 NA	
Knowledge and expertise 1 2 3 4 5 NA	
Teaching ability 1 2 3 4 5 NA	

#### Issues in Data Analysis

## **Rating of Individual Presentations**

#### Michael Proschan Survival Analysis

Scale: 1 = Poor 2 = Below Average 3 = Average	4 = Above Average 5 = Excellent NA= Not applicable
Criteria	Comments (Use back of page as necessary)
Content 1 2 3 4 5 NA	
Audio-visuals 1 2 3 4 5 NA	
Knowledge and expertise 1 2 3 4 5 NA	
Teaching ability 1 2 3 4 5 NA	

#### Issues in Data Analysis

## **Rating of Individual Presentations**

## Nancy Frasure-Smith Subgroup Analysis

2 = Below Average	4 = Above Average 5 = Excellent NA= Not applicable
Criteria	Comments (Use back of page as necessary)
Content 1 2 3 4 5 NA	
Audio-visuals 1 2 3 4 5 NA	
Knowledge and expertise 1 2 3 4 5 NA	
Teaching ability 1 2 3 4 5 NA	

#### Tab K Thursday and Friday, August 8-9, 2002

### Study Groups

8 Aug, Thursday	Study Group reports on RCT designs	All
	Evening: Graduation dinner and ceremony	
9 Aug, Friday	Study Group Reports on RCT designs	All
	~1:00 PM Adjournment	